Zoetis has announced the introduction of UlcerGold for the treatment and prevention of recurrence of gastric ulcers in horses and foals.
UlcerGold is presented in a syringe suitable for foals from four weeks of age and horses from 70 to 700kg and is supported by an information, training and client communication plan as a part of the Zoetis commitment to education and best practice.
Equine Gastric Ulcer Syndrome
(EGUS) is a serious and common condition affecting horses and foals. Approximately 90% of racehorses
, 60% of performance horses, 37% of leisure horses and 50% of foals
have been shown to be affected.
New UlcerGold is indicated to treat and prevent the recurrence of gastric ulcers in horses, administered once-daily for 28 consecutive days at the full dose of 4mg/kg bodyweight followed by the reduced dose of 1mg/kg bodyweight for a further 28 days.
It contains omeprazole, a proton pump inhibitor that suppresses gastric acid secretion. One syringe contains enough UlcerGold for a horse weighing up to 700kg. It can be used for foals as young as four weeks of age that weigh over 70kg and for breeding stallions.
Penny McCann, equine product manager for Zoetis UK Ltd said: “UlcerGold is an exciting addition to our equine POM-V portfolio. We have designed a training, education and business programme to help practices make sure they get the best from our new product, not only in terms of gastric ulceration treatment but also practice health.”